Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Declines By 86.1%

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the target of a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 9,100 shares, a decline of 86.1% from the May 15th total of 65,600 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 151,300 shares, the short-interest ratio is currently 0.1 days.

Chugai Pharmaceutical Stock Down 1.0%

CHGCY traded down $0.26 during midday trading on Friday, reaching $26.29. The company had a trading volume of 74,201 shares, compared to its average volume of 187,898. The business has a 50-day moving average of $26.53 and a two-hundred day moving average of $23.93. Chugai Pharmaceutical has a 1 year low of $15.26 and a 1 year high of $31.26. The company has a market cap of $86.52 billion, a P/E ratio of 34.14 and a beta of 0.68.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.19 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 21.53% and a net margin of 33.07%. The business had revenue of $1.89 billion for the quarter. On average, equities research analysts predict that Chugai Pharmaceutical will post 0.74 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.